1. The products under development are as follows:

(1)  ES135 protein drug

ES135 is a recombinant human acid fibroblast growth factor (rhFGF1) with 135 amino acids. Its indication for spinal cord injury has been investigated in approximately total 300 patients in phase 1, 2 and 3 clinical trials, respectively. Currently, it is  being tested in an exploratory clinical trial in patients with carpal tunnel syndrome for new indication of peripheral nerve injury.  

(2)  SM-1 :  a 3-in-1 combination sleeping aid

(3)   EPS221 small molecule drug: a selective serotonin reuptake inhibitors (SSRIs)

(4)   EPS222 small molecule drug: a calcium channel blocker for cardiovascular disease.

2. New product/Service in preparation

(1) Licensing in approved medicines and medical device

(2) Co-develop 505(b)2 new drugs with Pharmaceutical Partner(s) to expand R&D program